NCT02273713View on ClinicalTrials.gov

The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION)

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

154

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions

Esophageal CancerToxicity

Interventions

DRUG

Nab-paclitaxel

Nab-paclitaxel added to first line treatment oxaliplatin and capecitabine

Trial Locations (1)

1100 DD

Academic Medical Center, Medical Oncology, Amsterdam

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER